Drug Programs
Delivering on the Promise of AI Drug Discovery
Through GALILEO™, we’ve discovered 192 compounds for 26 targets, validated with multiple world class academic and corporate laboratories. Our programs have been validated with the leading academic and corporate research laboratories in the world.
Infectious Diseases
Our infectious disease program is developing the next generation of antivirals that have broader activity and demonstrate best-in-class antiviral characteristics.
1 Lead Preclinical POC
10+ Targets
50+ Assets In Vitro Validation
Oncology
Our Oncology program has discovered potential therapeutics for two broad spectrum oncology targets, AXL/BRD4.
2 Targets
20 Assets In Vitro Validation
Gastrointestinal Motility
Our program is focused on the growing evidence linking gastrointestinal dysmotility to numerous indications including weight disorders and neurological disorders.
1 Target
1 Asset In Vitro Validation
Autoimmune, Inflammation & Rare Diseases
We recently launched a program and completed in-silico discovery work for compounds against multiple targets related to ANCA-Associated Vasculitis (AAV)
ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis is a group of rare, life-threatening, immune disorders, which are characterized by a “necrotizing inflammatory process that predominantly affects small and medium-sized blood vessels” such as arterioles, capillaries, and venules.
There are three subtypes of AAV that include Granulomatosis with polyangiitis (GPA, previously Wegener’s disease), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, previously Churg-Strauss syndrome)
5 Targets
100+ Assets In Silico Discovery
